Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562

被引：110

作者：

Chan, Kin Tak ^{[1
]}

Li, Kwan ^{[1
]}

Liu, Shiu Lam ^{[1
]}

Chu, Kee Hung ^{[1
]}

Toh, Melvin ^{[1
]}

Xie, Wei Dong ^{[1
]}

机构：

[1] CK Life Sci Intl Holdings Inc, Dept Technol & Prod Dev, Hong Kong, Hong Kong, Peoples R China

来源：

CANCER LETTERS | 2010年 / 289卷 / 01期

关键词：

Cucurbitacin B; STAT3; Raf/MEK/ERK pathway; K562; Leukemia; BREAST-CANCER CELLS; WILBRANDIA-EBRACTEATA; ECBALLIUM-ELATERIUM; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; JAK/STAT PATHWAYS; TARGETING STAT3; CARCINOMA; GROWTH; PI3K/PTEN/AKT/MTOR;

D O I：

10.1016/j.canlet.2009.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Cucurbitacin B is a natural anti-cancer compound found in Cucurbitaceae. Although the anti-cancer activity of cucurbitacin B in human leukemia cells has been reported, the underlining mechanism is still unclear. To clarify its anti-cancer activity and the mechanism of action, five different leukemia cell lines (CCRF-CEM, K562, MOLT-4, RPMI-8226 and SR) of the National Cancer Institute panel were treated with cucurbitacin B. Leukemia cell growth was inhibited by cucurbitacin B with GI(50) ranged from 15.6 nM to 35.3 nM and the growth inhibition effect was attributable to G2/M phase arrest and apoptosis. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibits STAT3 activation and the Raf/MEK/ERK pathway in the K562 cells. Crown Copyright (C) 2009 Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：46 / 52

页数：7

共 39 条

[1]

Isolation of an anti-hepatotoxic principle from the juice of Ecballium elaterium [J].

Agil, A ;

Miró, M ;

Jimenez, J ;

Aneiros, J ;

Caracuel, MD ;

García-Granados, A ;

Navarro, MC .

PLANTA MEDICA, 1999, 65 (07) :673-675

[2]

Characterization of a novel oncogenic K-ras mutation in colon cancer [J].

Akagi, Kiwamu ;

Uchibori, Ryosuke ;

Yamaguchi, Kensei ;

Kurosawa, Keiko ;

Tanaka, Yoichiro ;

Kozu, Tomoko .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (03) :728-732

[3]

K-ras mutations in non-small-cell lung carcinoma:: A review [J].

Aviel-Ronen, Sarit ;

Blackhall, Fiona H. ;

Shepherd, Frances A. ;

Tsao, Ming-Sound .

CLINICAL LUNG CANCER, 2006, 8 (01) :30-38

[4]

Blaskovich MA, 2003, CANCER RES, V63, P1270

[5]

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia [J].

Case, Marian ;

Matheson, Elizabeth ;

Minto, Lynne ;

Hassan, Rosline ;

Harrison, Christine J. ;

Bown, Nick ;

Bailey, Simon ;

Vormoor, Josef ;

Hall, Andrew G. ;

Irving, Julie A. E. .

CANCER RESEARCH, 2008, 68 (16) :6803-6809

[6]

CHAMBLISS OI, 1996, SCIENCE, V153, P1392

[7]

Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors [J].

Chau, My N. ;

Banerjee, Partha P. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 377 (02) :627-631

[8]

Cucurbitacins and cucurbitane glycosides: structures and biological activities [J].

Chen, JC ;

Chiu, MH ;

Nie, RL ;

Cordell, GA ;

Qiu, SX .

NATURAL PRODUCT REPORTS, 2005, 22 (03) :386-399

[9]

STAT3 as a target for cancer drug discovery [J].

Costantino, Luca ;

Barlocco, Daniela .

CURRENT MEDICINAL CHEMISTRY, 2008, 15 (09) :834-843

[10]

Pathology and genetics of thyroid carcinoma [J].

Delellis, Ronald A. .

JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (08) :662-669

← 1 2 3 4 →